Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05163847 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults
A Phase 1 study, sponsored by FluGen.
- Completed
- Registry status
- Phase 1
- Development phase
- 303
- Enrollment target
NCT05163847 is a Phase 1 study that has completed, run by FluGen. The registered enrollment target is 303 participants.
The verdict
NCT05163847, a Phase 1 study, has completed, sponsored by FluGen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 303 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, double-dummy, placebo-controlled Phase 1b study evaluating the safety and immunogenicity of the investigational Cam2020 M2SR H3N2 influenza vaccine delivered IN alone or concomitantly with inactivated influenza vaccine (IIV) delivered IM to a healthy adult population age 65 to 85 years at time of enrollment.
Interventions
- OTHER IN Placebo
- OTHER IM Placebo
- BIOLOGICAL Cam2020 M2SR H3N2 influenza vaccine
- BIOLOGICAL Fluzone HD IIV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2022-06-14 |
| Est. Completion | 2022-11-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05163847
The ClinicalTrials.gov registry entry for NCT05163847 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 303 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is FluGen, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which IN Placebo is the first listed.
NCT05163847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05163847 about?
NCT05163847 is a clinical study titled "Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults". This is a randomized, double-blind, double-dummy, placebo-controlled Phase 1b study evaluating the safety and immunogenicity of the investigational Cam2020 M2SR H3N2 influenza vaccine delivered IN alone or concomitantly with inactivated influenza vaccine (IIV) delivered IM to a healthy adult populat...
What is the current status of trial NCT05163847?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 303 participants. The study started on 2022-06-14. Estimated completion is 2022-11-03.
What interventions are being tested in trial NCT05163847?
The interventions under investigation include: IN Placebo (OTHER), IM Placebo (OTHER), Cam2020 M2SR H3N2 influenza vaccine (BIOLOGICAL), Fluzone HD IIV (BIOLOGICAL).
Who is sponsoring clinical trial NCT05163847?
This trial is sponsored by FluGen, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.